HOME
ABOUT IAC
CONTACT
A-Z INDEX
DONATE
SHOP
SUBSCRIBE
Immunization Action Coalition
IAC Home
|
IAC Express
|
Issue 1544
Issue 1,544: January 13, 2021
Top Stories


Vaccine Information Statements


IAC Handouts


Featured Resources

Journal Articles and Newsletters


Education and Training


On the Lighter Side

 


Top Stories


“Allergic Reactions including Anaphylaxis after Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine—United States, December 14–23, 2020” published in MMWR

CDC published Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine—United States, December 14–23, 2020 in an Early Release MMWR on January 6. Key findings in the report appear below. 

  • Early safety monitoring detected 21 cases of anaphylaxis after administration of 1,893,360 first doses of Pfizer-BioNTech COVID-19 vaccine (11.1 cases per million vaccine doses)
  • 86% of anaphylaxis cases had symptom onset within 30 minutes of vaccination
  • 81% of these cases had a history of allergies or allergic reactions, including some with previous anaphylaxis events
  • 90% of these anaphylaxis cases after receipt of Pfizer-BioNTech COVID-19 vaccine occurred in women (a higher frequency than the 64% of recipients who are women)
  • Anaphylaxis is potentially life-threatening and requires preparedness to start immediate treatment if it happens
  • Anaphylaxis after Pfizer-BioNTech COVID-19 vaccine appears to be a rare event
  • CDC and FDA continue enhanced monitoring for anaphylaxis among recipients of COVID-19 vaccines

Based on these findings, CDC updated the allergy screening portion of the COVID-19 vaccination clinical considerations to state that contraindications to vaccination with either the Pfizer-BioNTech or Moderna COVID-19 vaccines include a history of severe allergic reaction after a previous dose of an mRNA COVID-19 vaccine or any of its components or immediate allergic reaction of any severity to a previous dose of an mRNA COVID-19 vaccine or any of its components (including polyethylene glycol [PEG]) or polysorbate). Additional details appear in CDC clinical considerations and in guidance on managing anaphylaxis.

Access the MMWR article in HTML format or in PDF format.

Related Links

Back to top
 


Don't get it wrong! Schedule COVID-19 vaccine dose #2 at 21 or 28 days, not sooner, say CDC and FDA

CDC and FDA each issued statements affirming the use of the standard dosing interval for the two authorized mRNA vaccines. 

On January 6, CDC revised Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. The portion regarding dosing intervals is summarized below:

  • Routine Scheduling. Do not schedule people to receive dose #2 earlier than recommended (i.e., 21 days for Pfizer-BioNTech or 28 days for Moderna).
  • Inadvertent Early Doses. Dose #2 inadvertently administered as much as 4 days too early (“grace period”) should be considered valid.
  • No Maximum Interval. There is no maximum interval between dose #1 and dose #2 for either vaccine. If dose #2 is administered beyond 21 or 28 days, there is no need to restart the series or repeat the dose.
  • Errors. Vaccine administration errors should be reported to the Vaccine Adverse Event Reporting System (VAERS).

Visit CDC's COVID-19 Vaccination: Clinical Considerations gateway page for more information. 

On January 4, the U.S. Food and Drug Administration (FDA) issued FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines. A portion of the statement is reprinted below.

Using a single dose regimen and/or administering less than the dose studied in the clinical trials without understanding the nature of the depth and duration of protection that it provides is concerning, as there is some indication that the depth of the immune response is associated with the duration of protection provided. If people do not truly know how protective a vaccine is, there is the potential for harm because they may assume that they are fully protected when they are not, and accordingly, alter their behavior to take unnecessary risks.

Related Links

Back to top
 


IAC launches "Vaccines: COVID-19" web page, directing you to the most important resources from CDC and others

The large body of COVID-19 vaccine information continues to expand daily. To help healthcare professionals stay up to date with current versions of COVID-19 resources for frontline vaccinators, IAC has launched its new Vaccines: COVID-19 web page at www.immunize.org/covid-19.
 


On this new web page, IAC has assembled links to key COVID-19 vaccine resource pages from CDC, IAC, and other medical and public health partners. To ease access, the web page is divided into topic areas, including: 

  • ACIP Recommendations
  • CDC COVID-19 Vaccination Information (main page)
  • Information about COVID-19 Vaccine Products
  • Vaccine Fact Sheets for Recipients and Caregivers (EUA Vaccines)
  • Clinic Resources and Tools (including vaccine administration, clinical considerations and special populations, safety, storage and handling, staff training materials, and reimbursement)
  • Patient Education Tools
  • Vaccine Confidence and Hesitancy
  • Frequently Asked Questions
  • Key Contacts for COVID-19 Vaccine Information and Policies

There are three ways to easily locate the new web page:

  • From the yellow box at the top of the IAC home page
  • Use www.immunize.org/covid-19
  • Go to the light blue band of tabs across the top of any IAC web page, choose the "Vaccines” tab, and then select “COVID-19”  

The Vaccines: COVID-19 web page will be updated frequently, so check back regularly for the most current information. 

Related Links 

Back to top
 


Reminder! Ask the Experts: COVID-19 web page answers your questions about COVID-19 vaccines

IAC recently created its Ask the Experts: COVID-19 web page to answer questions about the administration of mRNA COVID-19 vaccines authorized for emergency use by the FDA and recommended by CDC’s Advisory Committee on Immunization Practices. This Ask the Experts web page also provides links to CDC guidance that will likely evolve. The Ask the Experts: COVID-19 web page will grow as more information becomes available and whenever new vaccines are authorized.

IAC’s Ask the Experts gateway page leads you to 29 distinct web pages on a variety of topics comprising a total of more than 1,000 common or challenging questions and answers (Q&As) about vaccines and their administration. IAC wishes to recognize its team of experts: Kelly L. Moore, MD, MPH (lead); Carolyn Bridges, MD, FACP; William Atkinson, MD, MPH; and Deborah Wexler, MD.



Related Links

Back to top
 


HHS announces $22 billion in funding to support expanded COVID-19 testing and vaccination

In a January 6 press release, the Department of Health and Human Services (HHS) announced the Coronavirus Response and Relief Supplemental Appropriations Act will enable the CDC to provide more than $22 billion in funding to states, localities, and territories to support the nation’s response to the COVID-19 pandemic.

The $22 billion includes $19 billion for testing and $3 billion for vaccination activities. The funding is to be disbursed by January 19, 2021, to support testing and vaccination-related activities. Award recipients will include 64 jurisdictions including all 50 states, the District of Columbia, five major cities, and U.S. territories/islands. Funds will be allocated by a population-based formula.  

For more information about CDC’s ongoing support to states, please visit this CDC's COVID-19 Budget Fact Sheet gateway page.

Related Links

Back to top
 


HHS releases national strategic plan to address viral hepatitis in the U.S.

On January 7, the U.S. Department of Human Health Services (HHS) released its Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination 2021–2025 to address this serious, preventable public health threat.



The Viral Hepatitis Plan for 2021–25 focuses on hepatitis A, hepatitis B, and hepatitis C, the three most common hepatitis viruses affecting the health of the nation. The plan identifies populations that experience the highest burden of viral hepatitis so that federal agencies and other stakeholders can focus their resources for the greatest effect.

The Viral Hepatitis Plan includes five goals to guide planning efforts:

  • Prevent new viral hepatitis infections
  • Improve health outcomes of people with viral hepatitis
  • Reduce viral hepatitis-related disparities and health inequities
  • Improve viral hepatitis surveillance and data use
  • Achieve integrated, coordinated efforts that address the viral hepatitis epidemics among all partners and stakeholders

Related Links

Back to top
 


Voices for Vaccines releases new podcast, interviewing Stanley Plotkin on common COVID-19 vaccine questions

Voices for Vaccines (VFV) has posted a new entry in its Vax Talk podcast series: Let’s Ask Dr. Stanley Plotkin About These COVID-19 Vaccines. A description from their web page is reprinted below.

Millions of people have received a COVID-19 vaccine, which gives us a lot of information about the safety of these vaccines. We asked Dr. Stanley Plotkin, inventor of the rubella vaccine and co-inventor of a rotavirus vaccine, to join us to answer our questions and to make some predictions.



Voices for Vaccines is a national organization of parents and others who are dedicated to raising the level of the voices of immunization supporters. VFV invites everyone who values vaccines to become a member, use VFV tools in their own community, and sign up for VFV’s free newsletter. Please spread the word to your friends and colleagues to join VFV!

Related Links

Back to top
 


“Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020” published in MMWR

CDC published Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. A portion of the summary section is reprinted below. 

ACIP recommends preexposure vaccination with Ervebo for adults aged ≥18 years in the U.S. population who are at highest risk for potential occupational exposure to Ebola virus species Zaire ebolavirus because they are responding to an outbreak of EVD, work as health care personnel at federally designated Ebola treatment centers in the United States, or work as laboratorians or other staff at biosafety level 4 facilities in the United States. Recommendations for use of Ervebo in additional populations at risk for exposure and other settings will be considered and discussed by ACIP in the future.

Access the MMWR article in HTML format or in PDF format.

Related Link

  • MMWR gateway page provides access to MMWR Weekly, MMWR Recommendations and Reports, MMWR Surveillance Summaries, and MMWR Supplements

Back to top
 


IAC experts called on by news media

With vaccines in the news so much lately, journalists have sought out IAC experts to communicate the intricacies of running a quality vaccination program. Our insights have helped explain vaccines to the public and policy makers. We want to help them understand the complex work vaccinators do. We've reached mass markets and local stations, across the U.S. and overseas, via print, radio, television, blogs, and more. Here is a selection of our recent citations:

Back to top
 


Not-to-miss immunization articles in the news
 

These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.

Back to top
 


Vaccine Information Statements 


IAC posts revised French translation of the MMRV Vaccine Information Statement (VIS) 

IAC recently posted a revised French translation of the MMRV Vaccine (Measles, Mumps, Rubella, and Varicella) VIS. The translation was generously contributed by Georgetown Translators.  



Related Links

Back to top
 


IAC Handouts


New! IAC publishes “COVID-19 mRNA Vaccines What Clinic Personnel Need to Know,” a side-by-side comparison of Pfizer-BioNTech and Moderna COVID-19 vaccines

IAC has released its newest resource for healthcare professionals, COVID-19 mRNA Vaccines – What Clinic Personnel Need to Know, a 5-page summary offering a side-by-side comparison of the two FDA-authorized mRNA COVID-19 vaccines.
 
The table lists key characteristics of and resources for the Pfizer-BioNTech and Moderna mRNA vaccines. The resource presents information on each vaccine, including summary guidance and links to key resources available from CDC, FDA, and the vaccine manufacturers. Topics covered for each vaccine include:

  • Age indication
  • Presentation and packaging
  • Storage and handling
  • Vaccine preparation and administration
  • Vaccine safety
  • Vaccine product and administration codes



“COVID-19 mRNA Vaccines – What Clinic Personnel Need to Know” will be updated as new key resources become available. 
 
Related Links

Back to top
 


IAC updates “Decision to Not Vaccinate My Child – Declination Form”

IAC recently revised its Decision to Not Vaccinate My Child – Declination Form, adding “Declination Form” to the title and updating explanatory statements and references.



Related Links

Back to top
 


Featured Resources


CHOP’s Vaccine Education Center releases English- and Spanish-language versions of their COVID-19 mRNA Q&As

Children's Hospital of Philadelphia's (CHOP) Vaccine Education Center has released a 4-page, printable Q&A for the public titled COVID-19 mRNA Vaccines: What You Should Know.

View the handout in Spanish

 

As with their other Q&A sheets, these sheets can be photocopied for distribution, and the links can be added to websites. Print versions will be available in coming weeks.

Related Links

Back to top
 


In IAC’s “Video of the Week,” CDC's Dr. Amanda Cohn explains how ACIP advises CDC on use of vaccines

In this CDC video, Dr. Amanda Cohn, executive secretary of CDC’s Advisory Committee on Immunization Practices (ACIP), explains that ACIP consists of independent experts who debate and develop recommendations on using vaccines to control vaccine-preventable diseases, including COVID-19. The committee prioritizes safety and effectiveness while reviewing scientific evidence.  



Visit the whole collection at the VOTW archive.

Back to top
 


Use IAC’s expanded “Repository of Resources for Maintaining Immunization during the COVID-19 Pandemic” to catch up people who fell behind

IAC now offers more than 275 items in its Repository of Resources for Maintaining Immunization during the COVID-19 Pandemic gateway page to assist in maintaining routine immunization rates during the COVID-19 pandemic. Located on the website of the National Network of Immunization Coalitions, a project of IAC, this repository includes links to both national and state-level policies and guidance; advocacy materials, including talking points, webinars, press releases, articles, and social media posts; and telehealth resources.

These resources are intended for healthcare settings, state and local health departments, professional societies, immunization coalitions, advocacy groups, and the community to use in their efforts to sustain routine immunizations during the COVID-19 pandemic. The resources can be sorted and searched by date, title, geographic area, source, type, age category, or setting.

If you have a resource to suggest for the repository, please send a message to info@immunizationcoalitions.org.

Related Link

Back to top
 


Newly updated 65+ Flu Defense website offers resources for healthcare professionals serving older adults

Confident recommendations for flu vaccine from healthcare providers are powerfully persuasive and make a significant difference in decisions your patients make about vaccination. To assist you in maximizing protection for your patients, IAC, in collaboration with Seqirus, has updated the 65+ Flu Defense website at www.influenza-defense.org.

A new fact sheet on the site, The Importance of Preventing Influenza during a Pandemic, offers responses to help guide discussions with patients on the increased importance of flu vaccination during the COVID-19 pandemic. Age increases risks associated with COVID-19 infection including hospitalization and death. Preliminary studies suggest coinfection with influenza B and SARS-CoV-2 may elevate the risk of poor outcomes.



This helpful site includes information, tools, and tips for communicating with these adults about the scope and severity of influenza, for example:

Be sure to check out the updated 65+ Flu Defense website at www.influenza-defense.org to assist your efforts in protecting this vulnerable population.

Back to top
 


Great for workplace recognitions! IAC’s elegantly designed “Vaccines Save Lives” black enamel pins show how much you value vaccination.

IAC’s elegantly designed “Vaccines Save Lives” pins are meaningful gifts for people who care about immunization. The pin makes a refined statement in hard black enamel with gold lettering and edges, measuring 1.125" x 0.75".



The pin is a stick-through-post variety with the back end covered by a round rubber cap that holds the pin securely. A gold metal spring-lock clasp is also provided. 

Wear these pins on clothing, uniforms, and white coats to show that you value vaccines! They make a meaningful gift for people who care about immunization.

  

Click here for "Vaccines Save Lives" pin pricing and ordering information.

Back to top
 


Check out IAC’s new website Mass-Vaccination-Resources.org to find resources to help set up your mass vaccination clinics—new resources added!

The Immunization Action Coalition’s newest website, www.Mass-Vaccination-Resources.org, assists you in finding a wide range of ideas for developing your own mass vaccination clinics. Mass vaccination efforts will be useful for expediting flu vaccination this fall and may be needed after COVID-19 vaccines are licensed for use in large groups of people.

The website features a searchable list of resources for a variety of venues, including curbside, drive-through, and walk-through clinics; mobile medical vans; pharmacies; and schools. The database contains guidance documents, toolkits, publications, and other helpful resources that can be adapted to your community or individual healthcare setting.

Many of the documents were written in the pre-pandemic era and will need modification to ensure that additional protections, such as social distancing and personal protective equipment, help safeguard against COVID-19 transmission.

More resources have been added including:

In addition, IAC's archived, full-length webinar highlighting best practices and offering practical information for conducting a successful mass vaccination clinic, Mass Vaccination Clinics: Challenges and Best Practices, can also be viewed on www.Mass-Vaccination-Resources.org.
 
If you have a resource to suggest for the website, please send a message to info@mass-vaccination-resources.org
 
The webinar and the new website are supported by a medical education grant from Seqirus.

Related Links

Back to top
 


Journal Articles and Newsletters


“A Quality Improvement Learning Collaborative for Human Papillomavirus Vaccination” published in Pediatric Quality and Safety

In the January/February 2021 issue, Pediatric Quality and Safety published A Quality Improvement Learning Collaborative for Human Papillomavirus Vaccination. The senior author on the project is IAC’s Sharon G. Humiston, MD, MPH. The conclusion section is reprinted below.

This learning collaborative aimed to engage multiple AAP chapters and pediatric practices to teach QI skills and improve HPV vaccination rates using the Project ECHO telementoring platform. At the chapter level, the collaborative demonstrated success in satisfaction and in teaching the necessary skills to allow all participating chapters to go on to lead HPV QI learning collaboratives of their own. At the practice level, participants gained confidence in HPV vaccine communication and QI skills. The collaborative demonstrated early improvements in reducing missed opportunities to vaccinate, while the impact on HPV vaccination initiation and completion lagged. Future projects should be extended for more than 8 data cycles or use more frequent data collection to capture this change and further identify barriers to system-level change.

Back to top
 


“Population Mortality and Laws Encouraging Vaccination for Hospital Workers” published in Annals of Internal Medicine

In the January 5 issue, Annals of Internal Medicine published Population Mortality and Laws Encouraging Vaccination for Hospital Workers. The conclusion section is reprinted below. 

State laws promoting hospital worker vaccination against influenza may be effective in preventing pneumonia- and influenza-related deaths, particularly among elderly persons. Vaccinating hospital workers may substantially reduce the spread of influenza and protect the most vulnerable populations.

Back to top
 


Education and Training


Moderna scientists will offer two webinars regarding mRNA COVID-19 vaccination on January 14 and 19

Moderna will offer two webinars on mRNA vaccination against SARS-CoV-2, the virus that causes COVID-19. Ashfield Healthcare will coordinate the webinars on behalf of Moderna. CE credit will not be offered for these webinars.

On January 14, the webinar titled Important Information for Healthcare Providers about Moderna COVID-19 Vaccine will start at 11:00 a.m. (ET).  

Register for the January 14 webinar.

On January 19, the webinar Examining the SARS-CoV-2 Pandemic and the Moderna COVID-19 Vaccine: A Panel Discussion will be held from 7:00–8:00 p.m. (ET). This will be a conversational 1-hour presentation examining evolving epidemiology, the vaccine development timeline, the mRNA mechanism of action, and clinical data supporting an Emergency use Authorization (EUA).

Register for the January 19 webinar. 

Related Links

Back to top
 


On the Lighter Side


In this cute 1998 PSA from Nevada Health Division, a baby’s toys inform her that she can get the chickenpox vaccine

In this cute 1998 public service announcement (PSA) from the Nevada Health Division, a baby’s toys explain the importance of getting the chickenpox vaccine to help protect her from the potentially deadly disease. This PSA is part of a collection curated by vaccine expert William L. Atkinson, MD, MPH.



Previous PSAs featured in “On the Lighter Side” are available when viewing this Vimeo video.

Back to top

About IAC Express
The Immunization Action Coalition welcomes redistribution of this issue of IAC Express or selected articles. When you do so, please add a note that the Immunization Action Coalition is the source of the material and provide a link to this issue.

IAC Express is supported in part by Grant No. 6NH23IP922550 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of IAC and do not necessarily represent the official views of CDC.

IAC Express Disclaimer
ISSN: 1526-1786

Our mailing address:
Immunization Action Coalition
2550 University Avenue West, Suite 415 North
Saint Paul, MN 55114
Subscribe today to IAC Express: the up-to-date immunization information you need
IAC Express
IAC Express Home
2021 Issues
2020 Issues: July - December
2020 Issues: January - June
2019 Issues: July - December
2019 Issues: January - June
2018 Issues
20171997 Issues
Coronavirus (COVID-19) Information from IAC
Video of the Week
What You Should Know about the Johnson & Johnson COVID-19 Vaccine: In this Mayo Clinic Insights video, Melanie Swift, MD, explains how the Janssen (J&J) adenovirus vector vaccine is built. She explains that only one dose is needed and that this vaccine is very effective, especially considering it was studied in places where variant viruses were circulating.
Visit the VOTW archive
immunize.org homepage
Shop IAC
Follow Us
Follow IAC on Facebook
Follow IAC on Twitter
Follow IAC on YouTube
Read Dr. Wexler's monthly column for practical advice on vaccination topics
COVID-19 buttons and stickers
Try IAC's Facebook Frame
Vaccinating Adults:
A Step-by-Step Guide
Vaccinating Adults: A Step-by-Step Guide
IAC's 142-page book available for free download.
Calendar of Events
Conferences, meetings, and training opportunities
Conferences, meetings, and training opportunities
Patient Record Cards
Purchase IAC's patient record cards today!
Record cards for patients – child and teen, adult, and lifetime – are printed on durable paper and sized to fit in a wallet when folded
DVD Immunization Techniques
Purchase Immunization Techniques DVD
Every practice should have this award winning, "how-to" training video
Protect Newborns Guidebook
Protect Newborns Guidebook
Comprehensive guide Hepatitis B: What Hospitals Need to Do to Protect Newborns
Editorial Information
Editor
Deborah L. Wexler, MD
Associate Editors
John D. Grabenstein, RPh, PhD
Sharon Humiston, MD, MPH
Consulting Editors
Taryn Chapman, MS
Marian Deegan, JD
Courtnay Londo, MA
Technical Editor
Robin VanOss
 
- Guide to immunize.org -
A-Z INDEX
ABOUT IAC
IAC in the News
Staff
IAC History through Film
ACIP
RECOMMENDATIONS
ADOLESCENT VACCINATION
ADULT VACCINATION
ADULT VACCINATION GUIDE
ASK THE EXPERTS
Administering Vaccines
COVID-19
COVID-19 & Routine Vac
Hepatitis B
MMR
Storage and Handling
>> view all
BECKY PAYNE AWARD
BILLING & CODING
BIRTH DOSE GUIDEBOOK
CALENDAR OF EVENTS
CDC INFORMATION
CDC SCHEDULES
CLINIC TOOLS
Administering Vaccines
Adolescent Vaccination
Adult Vaccination
Screening for Contraindications
Storage & Handling
Vaccination and COVID-19
Vaccine Recommendations
>> view all
COALITIONS FOR
IMMUNIZATION
CONTRIBUTE TO IAC
COVID-19 RELATED
Ask the Experts: COVID-19
Ask the Experts: COVID-19
   & Routine Vac
Clinic Tools: Vaccination and
   COVID-19
Repository of Resources
Vaccines: COVID-19
DEAR COLLEAGUE LETTERS
16-year-old Visit
HPV
MenACWY Dose #2
DONATE TO IAC
EDUCATIONAL MATERIALS
EMAIL NEWS SERVICES
E-NEWSLETTER: IAC EXPRESS
EXEMPTIONS
FAQs
FAVORITES
FDA PACKAGE INSERTS
FILMS ABOUT IAC
GIVE BIRTH TO THE
END OF HEP B
HANDOUTS FOR
PATIENTS & STAFF
View All Materials
Administering Vaccines
Adolescent Vaccination
Adult Vaccination
Contraindications / Precautions
Documenting Vaccination
Healthcare Personnel
Managing Vaccine Reactions
Parent Handouts
Pregnancy and Vaccines
Q&As: Diseases and Vaccines
Q&As: Easy-to-Read
Schedules for Patients
Screening Checklists
Standing Orders Templates
Storage & Handling
Strategies & Policies
Temperature Logs
Top Handouts
Vaccine Confidence
Vaccine Recommendations
>> view all
HEP B BIRTH DOSE
HONOR ROLLS
Hep B Birth Dose
Mandatory Flu Vaccination for HCP
MenB Vaccination for Colleges
IAC EXPRESS
Subscribe to IAC Express
IMAGE LIBRARY
LAWS AND MANDATES
MANUFACTURERS
MASS VACCINATION
RESOURCES
NATIONAL ADULT &
INFLUENZA
IMMUNIZATION SUMMIT
NEWS & INFORMATION
NEWSLETTER SIGN UP
OFFICIAL RELEASES
ACIP
CDC
FDA
PACKAGE INSERTS
PARTNERS
PHARMACISTS
PHOTOS
POWERPOINT SLIDE SETS
PREGNANCY AND
VACCINES
PRESS ROOM
PROTECT NEWBORNS
FROM HEP B
PUBLICATIONS
IAC Express
Vaccinating Adults:
   A Step-by-Step Guide
Hepatitis B What Hospitals
   Need to Do to
   Protect Newborns
Needle Tips Archive
Vaccinate Adults Archive
Vaccinate Women Archive
REGISTRIES
SCHOOL VACCINATION REQUIREMENTS
SHOP IAC
DVD Immunization Techniques
Laminated Schedules
Patient Record Cards
Flu Vaccine Buttons and Stickers
"Vaccines Save Lives" Pins
SITE MAP
SLIDE SETS
STANDING ORDERS
STATE INFORMATION
Immunization Websites
Laws and Mandates for School Entry
Immunization Program Managers
SUBSCRIBE TO IAC EXPRESS
SUPPORT IAC
TALKING ABOUT VACCINES
Adjuvants & Ingredients
Autism
Importance of Vaccination
MMR Vaccine
Religious Concerns
Vaccine Safety
>> view all
TECHNICALLY SPEAKING
TRANSLATIONS
IAC Handouts
VISs
TRAVEL (INTERNATIONAL)
UNPROTECTED PEOPLE
STORIES
Chickenpox
Hepatitis B
Measles
Whooping Cough
>> view all
VACCINATING ADULTS:
A STEP-BY-STEP GUIDE
VACCINE INFORMATION
STATEMENTS
Translations
VACCINE
MANUFACTURERS
VACCINE POLICY &
LICENSURE
ACIP
FDA
WHO
VACCINE SAFETY
VACCINE TIMELINE
VACCINES
COVID-19
Hepatitis B
HPV (Human papillomavirus)
Influenza
Pertussis
Varicella
>> view all
VIDEO OF THE WEEK
VIDEO LIBRARY
VISs
Translations
WHAT'S NEW OR UPDATED AT IAC
Handouts
VISs and Translations
Web Pages
 
Immunization Action Coalition  •  2550 University Avenue West  •  Suite 415 North  •  Saint Paul, Minnesota  •  55114
tel 651-647-9009  •  fax 651-647-9131
 
 
 
This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 6NH23IP22550) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.